Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Ne uroe ndocrine Tumours (NETs)
|
|
- Agnes Burns
- 5 years ago
- Views:
Transcription
1 A service of the U.S. National Institutes of Health Trial record 1 of 4 for: CAMURUS Previous Study Return to List Next Study Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Ne uroe ndocrine Tumours (NETs) This study is currently recruiting participants. (see Contacts and Locations) Verified July 2015 by Camurus AB Sponsor: Camurus AB Collaborator: Novartis ClinicalTrials.gov Identifier: NCT First received: November 17, 2014 Last updated: July 3, 2015 Last verified: July 2015 History of Changes Information prov ided by (Responsible Party): Camurus AB Full Text View Tabular View No Study Results Posted Disclaimer How to Read a Study Record Purpose This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of tw o dosing regimens of CAM2029 in adult patients w ith acromegaly or a functional, w ell-differentiated NET, w ith carcinoid symptoms, treated for at least 2 months w ith Sandostatin LAR at doses of 10 mg, 20 mg, or 30 mg before the start of the Sandostatin LAR Last Dose Assessment Phase (Day -28). Condition Interv ention Phase Acromegaly Neuroendocrine Tumors Phase 2 Study Type: Study Design: Official Title: Interventional Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Tw o Patient Groups With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin LAR Resource links prov ided by NLM: MedlinePlus related topics: Cancer Carcinoid Tumors Drug Information available for: Octreotide acetate Octreotide Genetic and Rare Diseases Information Center resources: APUDoma Acromegaly Carcinoid Syndrome Carcinoid Tumor Neuroepithelioma U.S. FDA Resources Further study details as prov ided by Camurus AB:
2 Primary Outcome Measures: Pharmacokinetic (PK) profile of octreotide after each injection of CAM2029 as compared w ith baseline PK for Sandostatin Long-acting Release (LAR ) [ Time Frame: Baseline, Day 84 ] [ Designated as safety issue: No ] Secondary Outcome Measures: Number of adverse events and serious adverse events [ Time Frame: Baseline, Day 84 ] [ Designated as safety issue: Yes ] Safety of repeat dose of CAM2029 CAM2029 effect on insulin-like grow th factor (IGF-1) (Acromegaly) [ Time Frame: Baseline, Day 84 ] [ Designated as safety issue: No ] CAM2029 effect on grow th hormone (GH) (Acromegaly) [ Time Frame: Baseline, Day 84 ] [ Designated as safety issue: No ] Other Outcome Measures: To assess the symptoms of carcinoid syndrome (number of bow el movements and flushing) and the use of rescue medication versus baseline (by using patient diaries) (NET) [ Time Frame: Baseline, Day 84 ] [ Designated as safety issue: No ] Estimated Enrollment: 24 Study Start Date: January 2015 Estimated Study Completion Date: January 2016 Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure) Arms Experimental: CAM mg (NET) CAM2029 (octreotide FluidCrystal injection ) 10 mg, subcutaneous injection every tw o w eeks Experimental: CAM mg (NET) CAM2029 (octreotide FluidCrystal injection ) 20 mg, subcutaneous injection once monthly Experimental: CAM mg (Acromegaly) CAM2029 (octreotide FluidCrystal injection ) 10 mg, subcutaneous injection every tw o w eeks Experimental: CAM mg (Acromegaly) CAM2029 (octreotide FluidCrystal injection ) 20 mg, subcutaneous injection once monthly Assigned Interv entions Eligibility Ages Eligible for Study: Genders Eligible for Study: Accepts Healthy Volunteers: 18 Years and older Both No Criteria Inclusion Criteria: Acromegaly: NET: Male or female patients 18 years of age Acromegaly currently treated w ith Sandostatin LAR Male or female patients 18 years of age Functional, w ell-differentiated (Grade 1 or Grade 2) NET w ith symptoms of carcinoid syndrome (number of bow el movements and/or flushing) Currently treated w ith Sandostatin LAR for symptom control Exclusion Criteria: Acromegaly: Inadequate bone marrow function Abnormal coagulation or chronic treatment w ith w arfarin or coumarin derivates
3 NET: Impaired liver, cardiac and/or renal function Know n gallbladder, bile duct disease or pancreatitis Diabetes w ith poorly controlled blood glucose levels despite adequate therapy Hypothyroidisms not adequately treated Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, typical and atypical lung carcinoids, large cell neuroendocrine carcinoma and small cell carcinoma Carcinoid syndrome refractory to treatment w ith conventional doses of somatostatin analogues (SSAs) Inadequate bone marrow function Abnormal coagulation or chronic treatment w ith w arfarin or coumarin derivates Impaired liver, cardiac and/or renal function Know n gallbladder, bile duct disease or pancreatitis Short-bow el syndrome Diabetics w ith poorly controlled blood glucose levels despite adequate therapy Hypothyroidism, not adequately treated Contacts and Locations Choosing to participate in a study is an important personal decision. Talk w ith your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies. Please refer to this study by its ClinicalTrials.gov identifier: NCT Contacts Contact: Håkan Olsson, Clin Dir hakan.olsson@cam urus.com Locations France Hospices Civils de Lyon Bron, France Contact: Borson-Chazot, Dr CHU Rouen, Hôpital Charles Nicolle Rouen cedex, France Contact: Cailleux, Dr Germany Abteilung: Klinische Studien Bad Berka, Germany Contact: Hoersch, Dr Charité Campus Virchow Klinikum Berlin, Germany Contact: Pavel, Prof Universitätsklinikum Essen Essen, Germany Contact: Lahner, Dr University Hospital of Freiburg Freiburg, Germany Contact: Seufert, Dr Medizinische Klinik und Poliklinik IV München, Germany Contact: Schopohl, Dr Italy I.R.C.C.S. Ospedale Oncologico "Giovanni Paolo II" di Bari Bari, Italy
4 Contact: Guida, Dr Azienda Ospedaliero-Universitaria Careggi Firenze, Italy Contact: Brand, Dr RCCS Azienda Ospedaliera Universitaria San Martino IST Genova, Italy Contact: Ferone, Dr Fondazione Irccs Ca' Granda Milano, Italy Contact: Mantovani, Dr Università degli Studi di Napoli Federico II Napoli, Italy Contact: Pivonello, Dr Istituto Regina Elena Rome, Italy Contact: Baldelli, Dr Istituto Clinico Humanitas Rozzano, Italy Contact: Lania, Dr Sw eden Göteborgs Universitet Göteborg, Sw eden Contact: Johannsson, Dr Karolinska Universitetssjukhuset Stockholm, Sw eden Contact: Höybye, Dr Akademiska sjukhuset Uppsala, Sw eden Contact: Engström, Dr Akademiska sjukhuset Uppsala, Sw eden Contact: Welin, Dr Sponsors and Collaborators Cam urus AB Novartis Inv estigators Principal Investigator: Marianne Pavel, Professor Charité Campus Virchow Klinikum, Berlin, Germany More Information No publications provided Responsible Party: Camurus AB ClinicalTrials.gov Identifier: NCT History of Changes Other Study ID Numbers: HS Study First Received: November 17, 2014 Last Updated: July 3, 2015 Health Authority: Sw eden: Medical Products Agency Italy: The Italian Medicines Agency France: Agence Nationale de Sécurité du Médicament et des produits de santé Germany: Federal Institute for Drugs and Medical Devices Keyw ords provided by Camurus AB: acromegaly neuroendocrine tumour (NET) carcinoid syndrome octreotide Sandostatin LAR
5 Additional relevant MeSH terms: Acromegaly Apudoma Carcinoid Tumor Neuroendocrine Tumors Adenocarcinoma Adenoma Bone Diseases Bone Diseases, Endocrine Brain Diseases Carcinoma Central Nervous System Diseases Endocrine System Diseases Hyperpituitarism Hypothalamic Diseases Musculoskeletal Diseases Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Nervous System Diseases Neuroectodermal Tumors Pituitary Diseases Octreotide Antineoplastic Agents Antineoplastic Agents, Hormonal Gastrointestinal Agents Pharmacologic Actions Therapeutic Uses ClinicalTrials.gov processed this record on September 03, 2015
Previous Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: ASP 2215-cl-0101 Previous Study Return to List Next Study Dose Escalation Study Inv e stigating the Safe ty, Tole rability,
More informationPembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK /KEYNOTE-040)
A service of the U.S. National Institutes of Health Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials Trial
More informationNivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma (NIVAHL)
This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationTrial record 1 of 1 for: GO28341 Previous Study Return to List Next Study
1 von 5 11.12.2013 09:04 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: GO28341 Previous Study Return to List Next Study A Study of GDC-0068 in Combination With Fluoropyrimidine
More informationStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)
A service of the U.S. National Institutes of Health Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials Trial
More informationTrial record 1 of 1 for: Previous Study Return to List Next Study
1 von 6 14.01.2014 09:11 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: 2012-001834-33 Previous Study Return to List Next Study Study of Cabozantinib (XL184) Versus Prednisone
More informationStudy Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)
We are updating the design of this site. Learn more. Try the new test version at https://clinicaltrials.gov/beta/ Show less Find Studies About Studies Submit Studies Resources About Site Trial record 1
More informationTrial record 1 of 1 for: Previous Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: GMMG-HD6 Previous Study Return to List Next Study A Phase III Trial on the Effe ct of Elotuzumab in VRD Induction /Consolidation
More informationTrial record 1 of 6 for: mcl 3002 Previous Study Return to List Next Study
A service of the U.S. National Institutes of Health Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials Trial record
More informationProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
1 von 9 10.12.2013 09:03 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: UKM08_0057 Previous Study Return to List Next Study Prospective Trial for the Diagnosis and Treatment
More informationCondition or disease Intervention/treatment Phase. Drug: Gemcitabine. Drug: Oxaliplatin. Drug: Leucovorin. Drug: Fluorouracil. Drug: Atezolizumab
Find Studies About Studies Submit Studies Resources About Site A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic
More informationTrial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer The safety and scientific validity of this study is the responsibility
More informationA Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: CABL001X2101 Previous Study Return to List
More informationNow Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: Keynote 355 Previous Study Return to List
More informationPhase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Find Studies About Studies Submit Studies Resources About Site Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG The safety and scientific validity of
More informationPankoMab-GEX Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
1 von 7 13.01.2014 12:26 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: GEXMab25201 Previous Study Return to List Next Study PankoMab-GEX Versus Placebo as Maintenance Therapy
More informationAvelumab in M etastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: NCT01772004 Previous Study Return to List Next Study Avelumab in M etastatic or Locally Advanced Solid Tumors (JAVELIN Solid
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CC-5013-NHL-007 Previous Study Return to List Next Study Rituximab Plus Le nalidomide for Patie nts With Re lapse d / Re fractory
More informationChemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
More informationTrial record 1 of 1 for:
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,
More informationhttps://clinicaltrials.gov/ct2/show/nct ?term=inge-b&rank=1
Seite 1 von 6 A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: INGE-B Previous Study Return
More informationSOMATULINE DEPOT (lanreotide acetate)
SOMATULINE DEPOT (lanreotide acetate) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationLow-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML (AML-ViVA)
We updated the design of this site on December 18, 2017. Learn more. Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: AMLSG26-16/AML-ViVA Previous Study Return to
More informationTrial of S-1 M aintenance Therapy in M etastatic Esophagogastric Cancer (M ATEO)
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: AIO-YMO-0111 Previous Study Return to List Next Study Trial of S-1 M aintenance Therapy in M etastatic Esophagogastric Cancer
More informationPanitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
1 von 5 23.11.2011 10:52 Home Search Study Topics Glossary Full Text View Tabular View No Study Results Posted Related Studies Panitumumab After Resection of Liver Metastases From Colorectal Cancer in
More informationStudying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
A service of the U.S. National Institutes of Health Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY) This study is currently recruiting participants.
More informationAdjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: ACTICCA Previous Study Return to List Next Study Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation
More informationA Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
1 von 6 27.02.2014 08:45 A service of the U.S. National Institutes of Health A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With This study is not yet open for
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: somatostatin_analogs 7/2016 7/2017 7/2018 7/2017 Description of Procedure or Service Somatostatin, a hypothalamic
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationPreventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
Find Studies About Studies Submit Studies Resources About Site Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
More informationTrial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (NEOLAP)
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: neolap Previous Study Return to List Next Study Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced
More informationA service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
A service of the U.S. National Institutes of Health w Available: Final Rule for FDAAA 81 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: FENHYDPAI414 Previous Study Return to List Next
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationTRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationNal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (NIFE)
Try our beta test site IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for
More informationWe are updating the design of this site. Try the new test version at https://clinicaltrials.gov/beta/ Previous Study Return to List Next Study
We are updating the design of this site. Try the new test version at https://clinicaltrials.gov/beta/ Show less Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: GS-US-401-2076
More informationEfficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain
Page 1 of 8 A service of the U.S. National Institutes of Health Try our beta test site Trial record 1 of 1 for: 853-P-401 Previous Study Return to List Next Study Efficacy and Safety of Taken Three Times
More informationCandesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationTrial record 1 of 1 for: Denosumab as an add-on Neoadjuvant Treatment (GeparX) (GeparX)
This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationASCT After a Rituximab/Ibrutinib/Ara-c Containing induction in Generalized Mantle Cell Lymphoma
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: TRIANGLE AND ASCT Previous Study Return to List Next Study ASCT After a Rituximab/Ibrutinib/Ara-c Containing induction
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationEfficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
A service of the U.S. National Institutes of Health Trial record 3 of 67 for: BRAF V600E Previous Study Return to List Next Study Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
More informationSomatuline Depot. Somatuline Depot (lanreotide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.27 Subject: Somatuline Depot Page: 1 of 5 Last Review Date: December 8, 2017 Somatuline Depot Description
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013 ClinicalTrials.gov ID: NCT00168454 Study Identification Unique Protocol ID: 191622-077 Brief Title: A
More informationPerioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (ESOPEC)
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: esopec Previous Study Return to List Next Study Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients
More informationTrial record 1 of 1 for: 075-A-301 Previous Study Return to List Next Study
Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Comm... Page 1 of 10 A service of the U.S. National Institutes of Health
More informationEfficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With
More informationNivolumab nel carcinoma renale metastatico: esperienza italiana
Nivolumab nel carcinoma renale metastatico: esperienza italiana Ugo De Giorgi Istituto Tumori Romagna IRST IRCCS Meldola on behalf of the Italian EAP RCC Group Real world data from the Italian expanded
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More informationSeite 1 von 5 A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: BO18255 Previous Study Return
More informationSearch for studies: ClinicalTrials.gov Identifier: NCT
ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015 ClinicalTrials.gov ID: NCT01378962 Study Identification Unique Protocol ID: ML25514 Brief Title: A Study
More informationClinical Development in the Treatment of Carcinoid Syndrome. Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer
Clinical Development in the Treatment of Carcinoid Syndrome Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer Carcinoid Syndrome Heart Pulmonic and tricuspid valve thickening Stenosis
More informationPharmacy Prior Authorization Somatostatin Analogs Clinical Guideline
Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce
More informationA Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients (DELTA)
We updated the design of this site on December 18, 2017. Learn more. Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: TUD-DELTA1-063 Previous Study Return to List
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests
More informationEndocrine Pharmacology
Endocrine Pharmacology 17-2-2013 DRUGS AFFECTING THE ENDOCRINE SYSTEM The endocrine system is the system of glands, each of which secretes a type of hormone directly into the bloodstream to regulate the
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests
More informationVibration Intervention to Improve Bone and Muscle in Children With Cerebral Palsy
Vibration Intervention to Improve Bone and Muscle in Children With Cerebral Palsy This study has been completed. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute
More information3. Have baseline A1c or fasting glucose, thyroid-stimulating hormone (TSH), and electrocardiography (EKG) been checked?
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Somatostatin Analogs (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationA Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)
Page 1 of 5 Home Search Study Topics Glossary Search Study 1 of 1 for search of: NCT01235962 Previous Study Return to Search Results Next Study Full Text View Tabular View No Study Results Posted Related
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: 42603ATT3013 Previous Study Return to List Next Study A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS
More informationManaging Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide)
Managing Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide) INDICATION AND USAGE SIGNIFOR LAR (pasireotide) for injectable suspension is a somatostatin analog indicated for the treatment of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sandostatin, Sandostatin LAR Depot) Reference Number: CP.PHAR.40 Effective Date: 03.01.10 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log
More informationEvaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)
1 von 5 26.03.2013 15:16 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: Ago ovar 17 Previous Study Return to List Next Study Evaluation of Optimal Initial Treatment Duration
More informationTrial record 1 of 1 for:
This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationThyrotrophin Releasing Hormone
Thyrotrophin Releasing Hormone Frontiers of Hormone Research Vol. 1 M. Maroís, París S. Karger Basel München Paris London New York Sydney Workshop Conference on Thyrotrophin Releasing Hormone, Basel, April
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1091-7 Program Prior Authorization/Notification Medication Sandostatin (octreotide acetate) Note: Only the subcutaneous formulation
More informationThe effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes
The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes This trial is conducted in Europe and North America. The
More informationSelf-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues - the role for specialist dietitians and nurses
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues - the role for specialist dietitians and nurses Tara Whyand BSc MSc Neuroendocrine Tumour Research &
More informationAppendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
More informationPACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin)
ONC.000-092-861.10.0 PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG (goserelin) Name of the medicinal product Zoladex LA 10.8mg depot Qualitative and quantitative composition Goserelin acetate (equivalent to 10.8
More informationClinical Policy: Pasireotide (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: 03.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More informationA Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma (EPAZ)
A service of the U.S. National Institutes of Health Trial record 2 of 2 for: epaz Previous Study Return to List Next Study A Trial Comparing Two Medications as First Treatment in Elderly Patients With
More informationThe Ruxo-BEAT Trial in Patie nts With High-risk Polycythe mia Ve ra or High-risk Esse ntial Thrombocythe mia (Ruxo-BEAT)
A service of the U.S. National Institutes of Health Trial record 2 of 6 for: Ruxolitinib versus best available therapy Previous Study Return to List Next Study The Ruxo-BEAT Trial in Patie nts With High-risk
More informationPlatinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (TPExtreme)
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: TPExtreme Gortec Previous Study Return to List Next Study Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients
More informationCircle Yes or No Y N. [If yes, skip to question 29.] 2. Is the request for Sandostatin LAR? Y N. [If no, skip to question 5.] Prior Authorization
04/03/2016 Prior Authorization MERC MARICOPA ITEGRATED CARE - TXIX/XXI SMI (MEDICAID) Somatostatin Analogs and Somavert (AZ88) This fax machine is located in a secure location as required by HIPAA regulations.
More informationBeta test our new site. Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
1 von 6 14.08.2012 10:18 Beta test our new site. Home Search Study Topics Glossary Study 1 of 1 for search of: NCT00949364 Previous Study Return to Search Results Next Study Full Text View Tabular View
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1 trials currently open for patients with pheochromocytoma and/or paraganglima (from trials.gov) www.clinicaltrials.gov; Active PPGL trials Status Of Sunitinib In Patients With Recurrent
More informationoptions in Myeloablative HSCT
Should Busilvex we use AlloSCT in AML options in Myeloablative HSCT Reduced Intensity or Myeloablative preparative protocols? Moderator: Andrea Bacigalupo Reduced Intensity: Arnon Nagler Myeloablative:
More informationStudy Description. ClinicalTrials.gov Identifier: NCT
Find Studies About Studies Submit Studies Resources About Site A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal
More informationNeuro-endocrine and pancreatic non-adenocarcinomas. Marc Engelbrecht, AMC, Amsterdam
Neuro-endocrine and pancreatic non-adenocarcinomas Marc Engelbrecht, AMC, Amsterdam Pancreatic Tumors q Epithelial Exocrine q Mesenchymal Ductal Adenocarcinoma (85-95%) Metastasis Lymfoma Acinar Cell Carcinoma
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sandostatin, Sandostatin LAR) Reference Number: CP.CPA.149 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at
More informationWe updated the design of this site on December 18, Previous Study Return to List Next Study
We updated the design of this site on December 18, 2017. Learn more. Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: AC220-A-U302 Previous Study Return to List Next
More informationNEUROTOLOGY OPINIONS. Milano, Italy March 7 th - 8 th, 2019 PRELIMINARY PROGRAM.
PRELIMINARY PROGRAM NEUROTOLOGY OPINIONS Milano, Italy March 7 th - 8 th, 2019 Istituto di Ricovero e Cura a Carattere Scientifico Organizing Committee Prof. Mario Bussi Dr. Roberto Teggi Otorhinolaryngology
More informationHypothalamic & Pituitary Hormones
1 Hypothalamic & Pituitary Hormones Pharmacologic Applications: Drugs that mimic or block the effects of hypothalamic or pituitary hormones have the following applications: 1. Replacement therapy for hormone
More informationPiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)
Page 1 of 6 Home Search Study Topics Glossary Search Study 1 of 1 for search of: NCT01320254 Previous Study Return to Search Results Next Study Full Text View Tabular View No Study Results Posted Related
More informationNET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες
NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016 ClinicalTrials.gov ID: NCT00595413 Study Identification Unique Protocol ID: 27905 Brief Title: Atacicept
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationTable: CPT Codes / HCPCS Codes / ICD - 10 Codes ; Code Code Description; Information in the [brackets] below has been added for clarification
Table: CPT Codes / HCPCS Codes / ICD - 10 Codes ; Code Code Description; Information in the [brackets] below has been added for clarification purposes. Free ebook: Machiavelli's Laboratory "Ethics taught
More informationNeuroendocrine Tumors
Neuroendocrine Tumors FCDS Annual Conference Boca Raton Marriott at Boca Center July 28, 2016 Steven Peace, BS, CTR Anatomy and Physiology of the (Neuro)Endocrine System WHO Classification, Tumor Grade
More information